PURE Bioscience Forms Advisory Panel

PURE Bioscience Forms Advisory Panel

Tom Ridge, Tommy G. Thompson Among Inaugural Members
SAN DIEGO--(Business Wire)--
PURE Bioscience (NASDAQ:PURE), creator of the patented silver dihydrogen citrate
(SDC) antimicrobial, announced today the inaugural members of its newly formed
Advisory Panel: Tom Ridge, first Secretary of the U.S. Department of Homeland
Security and former Governor of Pennsylvania; Scott M. Russell, Ph.D., Professor
of Poultry Processing and Products Microbiology, Poultry Science Department of
the University of Georgia; and Tommy G. Thompson, former U.S. Secretary of
Health and Human Services and former four-term Governor of Wisconsin. Thompson
recently stepped down from the PURE Board and joined the Advisory Panel.

Michael L. Krall, President and CEO of PURE Bioscience, stated, "We are pleased
to announce the formation of the Advisory Panel and are honored to welcome its
first members. As we continue to validate additional applications for SDC in
many diverse industries and work to develop strategies for each industry, we
believe it will be invaluable to receive guidance from key leaders in various
market segments. Access to the experience, vision and contacts of leaders like
Tom Ridge, Dr. Scott Russell and Tommy Thompson exponentially strengthens our
business development program.

Secretary Tommy G. Thompson commented on his appointment to the Advisory Panel,
"I`m enthusiastic about the opportunity to continue to work with PURE by serving
on the Advisory Panel. Although the profile in the August 23rd edition of the
Sunday New York Times certainly helped raise awareness of SDC-based products, we
still have a lot of work to do. I remain committed to my mission of helping to
educate government agencies, businesses and consumers about the remarkable
benefits of SDC-based products and how they can be instrumental in preventing
transmission of dangerous human pathogens like MRSA, Norovirus and the pandemic
H1N1 swine flu virus."

Secretary Tom Ridge stated, "The unique chemical nature of SDC as a stable,
powerful yet non-toxic antimicrobial molecule renders it critically important to
the field of public safety. A multitude of possible applications exists for SDC
in domestic and international industry and government, including the military,
and I welcome the prospect of working with PURE Bioscience to accelerate its
business strategy to commercialize SDC as a platform technology."

Dr. Russell, added, "Silver dihydrogen citrate has immense market potential when
formulated as a recently EPA-registered food contact surface sanitizer as well
as when used as a processing aid in poultry processing and other types of food
production operations. SDC`s advantages in efficacy and safety translate to
increased efficiency and cost savings for production, packaging and distribution
companies. SDC could also provide much-needed protection for consumers. I am
excited about the opportunity to be involved with the introduction of PURE to
the food processing market and look forward to assisting PURE with the R&D,
market study and implementation of SDC as a next generation solution to the
challenges faced in the industry."

Patented Molecule Provides Powerful Protection

SDC is an electrolytically generated source of stabilized ionic silver. As a
platform technology, SDC is distinguished from competitors in the marketplace
because of its superior efficacy, low toxicity and the inability of bacteria to
form a resistance to it. The first new disinfectant active ingredient to be
registered by the EPA in more than 30 years, SDC-based disinfectants are
antiviral, antifungal and antibacterial, including a 30-second kill and 24-hour
residual protection against standard indicator bacteria and a two-minute kill
claim on MRSA (Methicillin-resistant Staphylococcus aureus), CA-MRSA, PVL-MRSA
and VRE (Vancomycin resistant Enterococcus faecium). Moreover, SDC-based
disinfectants are odorless, colorless, non-corrosive, non-flammable and are
compatible with other disinfecting and cleaning chemicals. In addition,
SDC-based disinfectants are included on the list published by the U.S.
Environmental Protection Agency (EPA) of antimicrobial products effective
against the 2009 H1N1 flu strain ("swine flu") based on their effectiveness
against other influenza A virus strains. Disinfectants containing PURE`s SDC
antimicrobial also meet the recommendation by the CDC for infection control of
H1N1 in both home and healthcare settings.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that
provide solutions to numerous global health challenges. PURE's proprietary high
efficacy/low toxicity bioscience technologies, including its silver dihydrogen
citrate-based antimicrobials, represent innovative advances in diverse markets
and lead today's global trend toward industry and consumer use of "green"
products while providing competitive advantages in efficacy and safety. Patented
SDC is an electrolytically generated source of stabilized ionic silver which
formulates well with other compounds. As a platform technology, SDC is
distinguished from competitors in the marketplace because of its superior
efficacy, reduced toxicity and the inability of bacteria to form a resistance to
it. PURE is headquartered in El Cajon, California (San Diego metropolitan area).
Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate," "project,"
"expect" or similar expressions. These statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and uncertainties that could
cause actual results to differ materially from the forward-looking statements.
Factors that would cause or contribute to such differences include, but are not
limited to, acceptance of the Company's current and future products and services
in the marketplace, the ability of the Company to develop effective new products
and receive regulatory approvals of such products, competitive factors,
dependence upon third-party vendors, and other risks detailed in the Company's
periodic report filings with the Securities and Exchange Commission. By making
these forward-looking statements, the Company undertakes no obligation to update
these statements for revisions or changes after the date of this release.

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.